Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Selexis SA ("Selexis") and Irvine Scientific Inc. ("Irvine") announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines. Irvine and Selexis will jointly present the results on Tuesday, October 13, 2009 at 11:45 AM at the BioProcess International Conference 2009 being held in Raleigh, North Carolina. Results of the program demonstrate the ability to produce gram quantities of therapeutic antibodies in 16 weeks using a CHO platform designed specifically for large scale cGMP manufacturing.

"By combining the world class media development capabilities found at Irvine Scientific with the speed and performance of the Selexis SURE Cell Line Development(TM) program a very powerful CHO based production platform has been developed," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "This platform can be implemented for the production large qualities of antibody or recombinant protein useful for preclinical and clinical development purposes, which is beneficial to both our licensees and service clients."

"Our scientists have been able to quickly develop and apply an advanced media program to support the speed and performance of the Selexis system in achieving gram per liter productivities in matter of weeks," said Makoto Shintani, Chief Executive Officer. "It is clear that this program can provide significant benefits to biotech companies in need of large quantities of antibodies or proteins quickly."